WO2012178184A3 - Removable protective shell for imaging agents and bioactive substances - Google Patents
Removable protective shell for imaging agents and bioactive substances Download PDFInfo
- Publication number
- WO2012178184A3 WO2012178184A3 PCT/US2012/044052 US2012044052W WO2012178184A3 WO 2012178184 A3 WO2012178184 A3 WO 2012178184A3 US 2012044052 W US2012044052 W US 2012044052W WO 2012178184 A3 WO2012178184 A3 WO 2012178184A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- imaging agents
- nanoparticles
- protective shell
- removable protective
- bioactive substances
- Prior art date
Links
- 239000012216 imaging agent Substances 0.000 title abstract 5
- 230000000975 bioactive effect Effects 0.000 title 1
- 230000001681 protective effect Effects 0.000 title 1
- 239000000126 substance Substances 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 4
- 229940079593 drug Drugs 0.000 abstract 4
- 239000002105 nanoparticle Substances 0.000 abstract 4
- 238000002604 ultrasonography Methods 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- 230000004888 barrier function Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000035699 permeability Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1878—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating
- A61K49/1881—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating wherein the coating consists of chelates, i.e. chelating group complexing a (super)(para)magnetic ion, bound to the surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Radiology & Medical Imaging (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides nanoparticles for delivery of imaging agents, drugs, and other molecules, such as genetic material. The nanoparticles have a core structure comprising the imaging agent and/or drug, and a shell structure that allows for water solubility. The shell structure further provides a barrier with limited water permeability that protects the core. The nanoparticles can be induced to release their cargo by treatment with ultrasound. Methods of delivering drugs and imaging agents are also provided, whereby the nanoparticles are delivered to tissues of interest in a substantially inert form, then activated using ultrasound to release the drugs or imaging agents.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161500585P | 2011-06-23 | 2011-06-23 | |
| US61/500,585 | 2011-06-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2012178184A2 WO2012178184A2 (en) | 2012-12-27 |
| WO2012178184A3 true WO2012178184A3 (en) | 2014-05-08 |
Family
ID=47423269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2012/044052 WO2012178184A2 (en) | 2011-06-23 | 2012-06-25 | Removable protective shell for imaging agents and bioactive substances |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2012178184A2 (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6559644B2 (en) * | 2001-05-30 | 2003-05-06 | Insightec - Txsonics Ltd. | MRI-based temperature mapping with error compensation |
| US20050214379A1 (en) * | 2004-01-02 | 2005-09-29 | Sandro Mecozzi | Encapsulation of chemical compounds in fluorous-core and fluorous-inner-shell micelles formed from semifluorinated-block or fluorinated-block copolymers |
| US20060293396A1 (en) * | 2005-01-14 | 2006-12-28 | Eastman Kodak Company | Amine polymer-modified nanoparticulate carriers |
| US20070243259A1 (en) * | 2006-04-17 | 2007-10-18 | Hsing-Wen Sung | Nanoparticles for protein/peptide delivery and delivery means |
| US20080044746A1 (en) * | 1998-11-20 | 2008-02-21 | Anderson Richard R | Permanent, removable tissue markings |
| US20100068522A1 (en) * | 2008-08-07 | 2010-03-18 | Nanoco Technologies Limited | Surface Functionalised Nanoparticles |
-
2012
- 2012-06-25 WO PCT/US2012/044052 patent/WO2012178184A2/en active Application Filing
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080044746A1 (en) * | 1998-11-20 | 2008-02-21 | Anderson Richard R | Permanent, removable tissue markings |
| US6559644B2 (en) * | 2001-05-30 | 2003-05-06 | Insightec - Txsonics Ltd. | MRI-based temperature mapping with error compensation |
| US20050214379A1 (en) * | 2004-01-02 | 2005-09-29 | Sandro Mecozzi | Encapsulation of chemical compounds in fluorous-core and fluorous-inner-shell micelles formed from semifluorinated-block or fluorinated-block copolymers |
| US20060293396A1 (en) * | 2005-01-14 | 2006-12-28 | Eastman Kodak Company | Amine polymer-modified nanoparticulate carriers |
| US20070243259A1 (en) * | 2006-04-17 | 2007-10-18 | Hsing-Wen Sung | Nanoparticles for protein/peptide delivery and delivery means |
| US20100068522A1 (en) * | 2008-08-07 | 2010-03-18 | Nanoco Technologies Limited | Surface Functionalised Nanoparticles |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012178184A2 (en) | 2012-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gao et al. | Drug nanocrystals: in vivo performances | |
| IL276643A (en) | Methods of enhancing drug delivery and effectiveness of therapeutic agents | |
| IL253000A0 (en) | Tricyclic pyrazolyl compounds, their use in the preparation of medicaments for the treatment of cancer and pharmaceutical compositions comprising them | |
| MX354216B (en) | Intravascular delivery of nanoparticle compositions and uses thereof. | |
| MY172519A (en) | Solid polymeric controlled release nanoparticle | |
| IL232308A (en) | C0mpounds as modulators of atp-binding cassette transporters, pharmaceutical compositions comprising them and their use in the preparation of medicaments for treating diseases and processes for preparation thereof | |
| WO2014057432A3 (en) | Multicomponent lipid nanoparticles and processes for the preparation thereof | |
| WO2016004048A3 (en) | Targeted conjugates and particles and formulations thereof | |
| EP2782632A4 (en) | Myocardial drug delivery apparatus and methods | |
| SI2299977T1 (en) | Liposomes for drug delivery and methods for preparation thereof | |
| BR112013011480A2 (en) | cancer treatment method, method of enhancing the therapeutic effectiveness of an anticancer drug, pmo1183 or a pharmaceutically acceptable salt thereof, use thereof and kit for use in cancer treatment | |
| SG11201502896XA (en) | Drug delivery conjugates containing unnatural amino acids and methods for using | |
| EP2600876A4 (en) | Combined drug delivery methods and apparatus | |
| EP2522338A4 (en) | Polymer nanoparticle injection formulation composition containing rapamycin with improved water solubility, preparation method thereof, and anticancer composition for combined use with radiotherapy | |
| WO2010083337A3 (en) | Composite nanostructures and methods for making and using them | |
| IL207546A0 (en) | Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases | |
| WO2010059253A3 (en) | Methods and compositions for localized agent delivery | |
| SG11201405159WA (en) | Functional pla-peg copolymers, the nanoparticles thereof, their preparation and use for targeted drug delivery and imaging | |
| EP2782631A4 (en) | Implantable solid-liquig drug delivery apparatus, formulations, and methods of use | |
| EP2413917A4 (en) | Drug delivery system and methods of use | |
| WO2011143201A3 (en) | Ratiometric combinatorial drug delivery | |
| WO2011133925A3 (en) | Targeted and light-activated cytosolic drug delivery | |
| IL206080A (en) | Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases | |
| WO2011055980A3 (en) | Composite of a protein comprising zinc oxide-bonding peptides and zinc oxide nanoparticles, and use thereof | |
| WO2012040331A3 (en) | Multistage nanoparticles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12803296 Country of ref document: EP Kind code of ref document: A2 |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 12803296 Country of ref document: EP Kind code of ref document: A2 |